Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?

Current Oncology Reports

Volumn 17, Issue 10, 2015, Pages

  Teplinsky, Eleonora ^a   Esteva, Francisco J ^b  

^a North Shore Long Island Center for Advanced Medicine   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Brain metastases; Central nervous systemic disease; HER2; Lapatinib; Leptomeningeal disease; Metastatic breast cancer; Novel agents; Pertuzumab; T DM1; Targeted therapies; Trastuzumab

Indexed keywords

BUPARLISIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; NAVELBINE; NERATINIB; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; VASCULOTROPIN; ANTIBODY CONJUGATE; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM METASTASIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG USE; ENCAPSULATION; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; REVIEW; SOLID TUMOR; BRAIN NEOPLASMS; BREAST NEOPLASMS; CEREBROSPINAL FLUID; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; FEMALE; PATHOLOGY; SECONDARY;

ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNOCONJUGATES; MOLECULAR TARGETED THERAPY; QUINAZOLINES; RECEPTOR, ERBB-2; TRASTUZUMAB;

EID: 84940504224     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-015-0471-z     Document Type: Review

References (108)

1. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol. 2005;167(4):913–20.
2. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22(17):3608–17.
3. Pestalozzi BC. Brain metastases and subtypes of breast cancer. Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2009;20(5):803–5.
4. Lin NU. Breast cancer brain metastases: new directions in systemic therapy. Ecancer Med Sci. 2013;7:307.
5. Singh JC, Jhaveri K, Esteva FJ. HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. Br J Cancer. 2014;111(10):1888–98.
6. Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(19):2100–8. This is an ASCO clinical practice evidence-based guideline on the management of patients with advanced HER2-positive breast cancer and brain metastases.
7. Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, et al. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res BCR. 2012;14(5):R129.
8. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2006;17(6):935–44.
9. Chien AJ, Rugo HS. Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013;137(1):1–12.
10. Hess KR, Esteva FJ. Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Res Treat. 2013;137(2):449–55.
11. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(14):4834–43.
12. Fornier M, Esteva FJ, Seidman AD. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin Oncol. 2000;27(6 Suppl 11):38–45.
13. Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(19):2078–99. This is an ASCO clinical practice evidence-based guideline on the systemic management of patients with advanced HER2-positive breast cancer.
14. Esteva FJ, Yu D, Hung MC, Hortobagyi GN. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol. 2009;7(2):98–107. doi:10.1038/nrclinonc.2009.216.
15. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene. 2007;26(25):3637–43.
16. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.
17. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265–74.
18. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(7):1800–8.
19. Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007;110(5):965–72.
20. Nahta R, Esteva FJ. In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells. Cancer Chemother Pharmacol. 2004;53(2):186–90.
21. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol. 2009;27(12):1999–2006.
22. Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Rudas M, Mader RM, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol. 2007;25(25):3853–8.
23. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–43.
24. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112(3):533–43.
25. Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol. 2008;26(18):2999–3005.
26. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008;26(34):5544–52.
27. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124–30.
28. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012;30(21):2585–92.
29. Esteva FJ, Franco SX, Hagan MK, Brewster AM, Somer RA, Williams W, et al. An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. Oncologist. 2013;18(6):661–6.
30. Johnston S, Pippen Jr J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27(33):5538–46.
31. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004;64(7):2343–6.
32. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69(24):9330–6. doi:10.1158/0008-5472.CAN-08-4597.
33. Cortes J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(14):1594–600.
34. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19. This is a randomized phase III trial (CLEOPATRA) which demonstrated the benefit of pertuzumab in the treatment of advanced HER2-positive breast cancer. Pertuzumab was approved by the United States Food and Drug Administration on the basis of this study.
35. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–34. This publication reported on the survival data from the CLEOPATRA trial, demonstrating a 15.7 month improvement in overall survival with the addition of pertuzumab. The marked improvement in survival of patients with HER2-positive breast cancer in part explains the increasing incidence and prevalence of brain metastases in this patient population.
36. Isakoff SJ, Baselga J. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2011;29(4):351–4.
37. Krop I, Winer EP. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20(1):15–20.
38. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28(16):2698–704.
39. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91. This is a randomized phase III trial (EMILIA) which demonstrated the benefit of T-DM1 in the treatment of advanced HER2-positive breast cancer. T-DM1 was approved by the United States Food and Drug Administration on the basis of this study.
40. Krop IE, Kim SB, Gonzalez-Martin A, LoRusso PM, Ferrero JM, Smitt M, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(7):689–99.
41. Lim E, Lin NU. Updates on the management of breast cancer brain metastases. Oncology. 2014;28(7):572–8.
42. Fokstuen T, Wilking N, Rutqvist LE, Wolke J, Liedberg A, Signomklao T, et al. Radiation therapy in the management of brain metastases from breast cancer. Breast Cancer Res Treat. 2000;62(3):211–6.
43. Abouharb S, Ensor J, Loghin ME, Katz R, Moulder SL, Esteva FJ, et al. Leptomeningeal disease and breast cancer: the importance of tumor subtype. Breast Cancer Res Treat. 2014;146(3):477–86. This is a retrospective study evaluating survival on the basis of tumor subtype in patients with leptomeningeal disease. This study demonstrated that while leptomeningeal disease carries a poor prognosis, patients with HER2-positive breast cancer have the best outcome.
44. Anders CK, Deal AM, Miller CR, Khorram C, Meng H, Burrows E, et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer. 2011;117(8):1602–11.
45. Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer. 2008;112(11):2359–67.
46. Niwinska A, Murawska M, Pogoda K. Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases. Cancer. 2010;116(18):4238–47.
47. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2008;19(7):1242–8.
48. Sperduto PW, Kased N, Roberge D, Chao ST, Shanley R, Luo X, et al. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. J Neuro-Oncol. 2013;112(3):467–72.
49. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70(2):510–4.
50. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745–51.
51. Tsao MN, Rades D, Wirth A, Simon SL, Danielson BL, Gaspar LE, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis/es: An American Society for Radiation Oncology evidence-based guideline (2012) https://www.astro.org/Clinical-Practice/Guidelines/Brain-metastases.aspx: The American Society for Radiation Oncology (ASTRO); 2012. This is a clinical evidence-based guideline from the American Society for Radiation Oncology which reviewed the evidence for radiotherapeutic and surgical management of patients with newly diagnosed brain metastases. This guideline contributes to the standard of care for HER2-positive metastatic breast cancer patients with newly diagnosed brain metastases.
52. Oncology NCPGi. Central Nervous System Cancers http://www.nccn.org: National Comprehensive Cancer Network; 2013 [cited 2013 June 18]. Version 2.2013.
53. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol. 2000;18(11):2349–51.
54. Patil A, Sherbet GV. Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain. Cancer Lett. 2015;358(2):93–9.
55. Mehta AI, Brufsky AM, Sampson JH. Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev. 2013;39(3):261–9.
56. Okita Y, Narita Y, Suzuki T, Arita H, Yonemori K, Kinoshita T, et al. Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases. Mol Clin Oncol. 2013;1(6):995–1001. This study evaluated breast cancer patients with brain metastases and demonstrated that the HER2-positive patients who received trastuzumab exhibited a longer survival time after brain metastases when compared to the HER2-positive patients who did not receive trastuzumab and the HER2-negative patients. This study recommends extended trastuzumab therapy following the diagnosis of brain metastases in HER2-positive patients.
57. Kirsch DG, Ledezma CJ, Mathews CS, Bhan AK, Ancukiewicz M, Hochberg FH, et al. Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol. 2005;23(9):2114–6. author reply 6–7.
58. Le Scodan R, Jouanneau L, Massard C, Gutierrez M, Kirova Y, Cherel P, et al. Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer. 2011;11:395.
59. Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res BCR. 2008;10(1):R20.
60. Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer. 2009;100(6):894–900.
61. Park IH, Ro J, Lee KS, Nam BH, Kwon Y, Shin KH. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2009;20(1):56–62.
62. Church DN, Modgil R, Guglani S, Bahl A, Hopkins K, Braybrooke JP, et al. Extended survival in women with brain metastases from HER2 overexpressing breast cancer. Am J Clin Oncol. 2008;31(3):250–4.
63. Bartolotti M, Franceschi E, Brandes AA. Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts. Future Oncol (London, England). 2013;9(11):1653–64.
64. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57(2):173–85.
65. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anti-Cancer Drugs. 2007;18(1):23–8.
66. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87(5):586–92.
67. Pitz MW, Desai A, Grossman SA, Blakeley JO. Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neuro-Oncol. 2011;104(3):629–38.
68. Park WY, Kim HJ, Kim K, Bae SB, Lee N, Lee KT, et al. Intrathecal trastuzumab treatment in patients with breast cancer and leptomeningeal carcinomatosis. Cancer Res Treat Off J Kor Cancer Assoc. 2015. doi:10.4143/crt.2014.234.
69. Bousquet G, Darrouzain F, de Bazelaire C, Ternant D, Barranger E, Winterman S, et al. Intrathecal trastuzumab halts progression of CNS metastases in breast cancer. J Clin Oncol. 2014. doi:10.1200/JCO.2012.44.8894.
70. Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, et al. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res Treat. 2013;139(1):13–22. This is a systematic review of the use of intrathecal trastuzumab to treat meningeal carcinomatosis in HER2-positive metastatic breast cancer patients, demonstrating its safety and potential efficacy.
71. Martens J, Venuturumilli P, Corbets L, Bestul D. Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases. Acta Oncol. 2013;52(1):175–8.
72. Oliveira M, Braga S, Passos-Coelho JL, Fonseca R, Oliveira J. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res Treat. 2011;127(3):841–4.
73. Ferrario C, Davidson A, Bouganim N, Aloyz R, Panasci LC. Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2009;20(4):792–5.
74. Colozza M, Minenza E, Gori S, Fenocchio D, Paolucci C, Aristei C, et al. Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemother Pharmacol. 2009;63(6):1157–9.
75. Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2008;19(11):1978–80.
76. Raizer J, Pentsova E, Omuro A, Lin N, Nayak L, Quant E, Kumthekar P. Phase I trial of intrathecal trastuzumab in HER2-positive leptomeningeal metastases. Neuro Oncol. 2014;16 (suppl 5):v19. doi:10.1093/neuonc/nou237.46.
77. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008;26(12):1993–9.
78. Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(4):1452–9.
79. Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64–71. The LANDSCAPE study is a single arm phase 2 trial evaluating the combination of lapatinib and capecitabine in HER2-positive metastatic breast cancer patients with previously untreated brain metastases. This combination was active with an objective CNS response of 65.9% and according to the ASCO guidelines, this combination is felt to be a viable alternative first-line treatment option for brain metastases patients, especially in those patients with asymptomatic low-volume disease.
80. Shawky H, Tawfik H. All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer—a phase II study. J Egypt Natl Cancer Inst. 2014;26(4):187–94.
81. Pivot X, Manikhas A, Zurawski B, Chmielowska E, Karaszewska B, Allerton R, et al. CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015;33(14):1564–73. The randomized, phase 3 CEREBREL study evaluated the incidence of CNS metastases as first site of relapse in HER2-positive metastatic breast cancer patients receiving lapatinib-capecitabine or trastuzumab-capecitabine. There was no difference detected between the two groups. The study was deemed inconclusive for its primary endpoint and does not support using lapatinib to prevent the development of breast cancer brain metastases.
82. Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, et al. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31. J Clin Oncol. 2015;33(14):1574–83.
83. Lin NU. Weighing the options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer. J Clin Oncol. 2015;33(14):1530–3.
84. de Azambuja E, Zardavas D, Lemort M, Rossari J, Moulin C, Buttice A, et al. Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial. Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2013;24(12):2985–9.
85. Pircher M, Mlineritsch B, Fridrik MA, Dittrich C, Lang A, Petru E, et al. Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial. Anticancer Res. 2015;35(1):517–21.
86. Lin NU, Eierman W, Greil R, Campone M, Kaufman B, Steplewski K, et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neuro-Oncol. 2011;105(3):613–20.
87. Swain SM, Baselga J, Miles D, Im YH, Quah C, Lee LF, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2014;25(6):1116–21. This is a subset analysis of the CLEOPATRA study which evaluated the incidence of CNS metastases in HER2-positive metastatic breast cancer patients treated with pertuzumab, trastuzumab and docetaxel. The incidence of CNS metastases as the first site of disease progression was similar between the two arms but the use of pertuzumab did delay the onset of CNS disease.
88. Torres S, Maralani P, Verma S. Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases. BMJ Case Rep. 2014. doi:10.1136/bcr-2014-205680.
89. Bartsch R, Berghoff AS, Preusser M. Breast cancer brain metastases responding to primary systemic therapy with T-DM1. J Neuro-Oncol. 2014;116(1):205–6.
90. Carlson JA, Nooruddin Z, Rusthoven C, Elias A, Borges VF, Diamond JR, et al. Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. Neuro Oncol. 2014;16(7):1006–9.
91. Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2015;26(1):113–9. This exploratory analysis of the EMILIA trial evaluated the incidence of CNS metastases after treatment with T-DM1 versus treatment with lapatinib-capecitabine and treatment efficacy among patients with pre-existing CNS metastases. The rate of CNS progression was similar between the two arms but in patients with treated, asymptomatic CNS metastases at baseline, T-DM1 was associated with improved survival when compared to lapatinib-capecitabine.
92. Peddi PF, Hurvitz SA. PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer. J Neuro-Oncol. 2014;117(1):7–13.
93. Baselga J, Campone M, Piccart M, Burris 3rd HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9.
94. O’Reilly T, McSheehy PM, Kawai R, Kretz O, McMahon L, Brueggen J, et al. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemother Pharmacol. 2010;65(4):625–39.
95. Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125–32.
96. Andre F, O’Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15(6):580–91.
97. Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Ianzano ML, et al. Multiorgan metastasis of human HER-2+ breast cancer in Rag2−/−;Il2rg−/− mice and treatment with PI3K inhibitor. PLoS One. 2012;7(6):e39626.
98. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012;30(3):282–90.
99. Kim LS, Huang S, Lu W, Lev DC, Price JE. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis. 2004;21(2):107–18.
100. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8(8):610–22.
101. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997;151(6):1523–30.
102. Kerbel RS, Viloria-Petit A, Klement G, Rak J. ‘Accidental’ anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer. 2000;36(10):1248–57.
103. Lu YS, Chen TW, Lin CH, Yeh DC, Tseng LM, Wu PF, et al. Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21(8):1851–8.
104. Lin NU, Gelman RS, Younger JW, et al. Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients with breast cancer brain metastases. J Clin Oncol. 2013;31 (suppl; abstr 513). http://meetinglibrary.asco.org/content/113007-132
105. Saura C, Garcia-Saenz JA, Xu B, Harb W, Moroose R, Pluard T, et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2014;32(32):3626–33.
106. Jhaveri K, Hamilton EP, Miller K, et al. A phase 1b trial of blood-brain barrier (BBB)-penetrant tyrosine kinase inhibitor (TKI) tesevatinib in combination with trastuzumab for patients with HER2+ metastatic breast cancer (MBC). J Clin Oncol. 2015;33 (suppl; abstr 608).
107. Cortes JDV, Ro J, et al. editor. Randomized Phase II trial of afatinib alone or with vinorelbine versus investigator’s choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or lapatinib based therapy: LUX-Breast 3. Poster P5-19-07. San Antonio Breast Cancer Symposium (SABCS) 2014 Congress; 2014 9–13 December 2014; San Antonio, TX.
108. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs. 2009;23(1):35–58.